BDBM622518 US20230312583, Compound I-14

SMILES CC(C)n1cnc2ccc3cnc(Nc4cc(Oc5ccccc5)c(cn4)N4CCNCC4)nc3c12

InChI Key InChIKey=YXNQYHXLQNMLSB-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 622518   

TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 11.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 8.34nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetMast/stem cell growth factor receptor Kit(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 70.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 436nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 46.1nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Shengke Pharmaceuticals (Jiangsu)

US Patent
LigandPNGBDBM622518(US20230312583, Compound I-14)
Affinity DataIC50: 23.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2023
Entry Details
Go to US Patent